产品
编 号：F534645
分子式：C27H29ClN6O5
分子量：553.01
分子式：C27H29ClN6O5
分子量：553.01
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 947331-05-7
产品详情
生物活性：
Allisartan isoproxil (ALS-3) is an orally potent, selective, non-peptide inhibitor of Angiotensin II Type 1. Allisartan isoproxil is also an antihypertensive agent. Allisartan isoproxil may inhibit angiotensin-aldosterone system and oxidative stress. Allisartan isoproxil lowers blood pressure and protects the organs, preventing cerebrovascular damage. Allisartan isoproxil (80-320 mg/kg/d) has shown toxicity in rat models by targeting liver organs.
体内研究：
Allisartan isoproxil 的代谢途径相对简单，Allisartan isoproxil 在胃肠道吸收过程中通过酯酶完全直接转化为EXP-3174。Allisartan isoproxil (20、80和320 mg/kg；口服；26 周) 在 80-320 mg/kg/天的剂量下，会减轻 Sprague-Dawley 大鼠的体重。Allisartan isoproxil (30mg /kg/天；口服；55 周) 显著降低卒中易感肾血管性高血压大鼠 (RHR-SP) 的相关死亡，延长寿命。Animal Model:Femal and male Sprague-Dawley rats
Dosage:20, 80 and 320 mg/kg
Administration:
Result:Decreased body-weight gain at 320 mg/kg/day in both sexes as well as at the 80-mg/kg/day dose in females.Decreased erythrocyte parameters in males, and decreased heart weight and exacerbation of chronic progressive nephropathy (CPN) severity in males at 80 and 320 mg/kg/day.
Allisartan isoproxil (ALS-3) is an orally potent, selective, non-peptide inhibitor of Angiotensin II Type 1. Allisartan isoproxil is also an antihypertensive agent. Allisartan isoproxil may inhibit angiotensin-aldosterone system and oxidative stress. Allisartan isoproxil lowers blood pressure and protects the organs, preventing cerebrovascular damage. Allisartan isoproxil (80-320 mg/kg/d) has shown toxicity in rat models by targeting liver organs.
体内研究：
Allisartan isoproxil 的代谢途径相对简单，Allisartan isoproxil 在胃肠道吸收过程中通过酯酶完全直接转化为EXP-3174。Allisartan isoproxil (20、80和320 mg/kg；口服；26 周) 在 80-320 mg/kg/天的剂量下，会减轻 Sprague-Dawley 大鼠的体重。Allisartan isoproxil (30mg /kg/天；口服；55 周) 显著降低卒中易感肾血管性高血压大鼠 (RHR-SP) 的相关死亡，延长寿命。Animal Model:Femal and male Sprague-Dawley rats
Dosage:20, 80 and 320 mg/kg
Administration:
Result:Decreased body-weight gain at 320 mg/kg/day in both sexes as well as at the 80-mg/kg/day dose in females.Decreased erythrocyte parameters in males, and decreased heart weight and exacerbation of chronic progressive nephropathy (CPN) severity in males at 80 and 320 mg/kg/day.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备